Zacks: Brokerages Expect Aptose Biosciences Inc. (NASDAQ:APTO) to Post -$0.13 Earnings Per Share

Wall Street brokerages expect Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) to announce earnings of ($0.13) per share for the current quarter, Zacks reports. Zero analysts have made estimates for Aptose Biosciences’ earnings. The highest EPS estimate is ($0.12) and the lowest is ($0.14). Aptose Biosciences reported earnings of ($0.16) per share during the same quarter last year, which would indicate a positive year-over-year growth rate of 18.8%. The business is scheduled to report its next quarterly earnings report on Tuesday, November 5th.

According to Zacks, analysts expect that Aptose Biosciences will report full year earnings of ($0.59) per share for the current year, with EPS estimates ranging from ($0.68) to ($0.55). For the next financial year, analysts forecast that the company will post earnings of ($0.69) per share, with EPS estimates ranging from ($0.69) to ($0.68). Zacks’ earnings per share averages are an average based on a survey of sell-side analysts that cover Aptose Biosciences.

Aptose Biosciences (NASDAQ:APTO) (TSE:APS) last released its earnings results on Tuesday, August 6th. The biotechnology company reported ($0.13) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.14) by $0.01.

Several research analysts recently commented on APTO shares. HC Wainwright lowered their target price on Aptose Biosciences from $8.50 to $6.00 and set a “buy” rating for the company in a research note on Wednesday, August 7th. Roth Capital reissued a “buy” rating on shares of Aptose Biosciences in a research note on Thursday, May 23rd. Finally, Zacks Investment Research cut Aptose Biosciences from a “buy” rating to a “hold” rating in a research note on Monday. One research analyst has rated the stock with a hold rating and six have given a buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $5.25.

APTO opened at $2.38 on Tuesday. Aptose Biosciences has a 12 month low of $1.57 and a 12 month high of $3.20. The stock has a market capitalization of $148.04 million, a price-to-earnings ratio of -2.77 and a beta of 1.61. The company has a debt-to-equity ratio of 0.04, a current ratio of 11.27 and a quick ratio of 11.27. The business has a fifty day moving average price of $2.65 and a 200 day moving average price of $2.16.

A number of hedge funds and other institutional investors have recently made changes to their positions in APTO. Point72 Asset Management L.P. purchased a new stake in Aptose Biosciences during the 2nd quarter worth about $5,742,000. Man Group plc purchased a new stake in Aptose Biosciences during the 2nd quarter worth about $3,867,000. DRW Securities LLC lifted its holdings in Aptose Biosciences by 30.8% during the 2nd quarter. DRW Securities LLC now owns 3,347,018 shares of the biotechnology company’s stock worth $8,736,000 after buying an additional 788,560 shares during the last quarter. Sigma Planning Corp purchased a new stake in Aptose Biosciences during the 2nd quarter worth about $572,000. Finally, Sanders Morris Harris LLC purchased a new stake in Aptose Biosciences during the 2nd quarter worth about $572,000. 6.74% of the stock is owned by institutional investors.

Aptose Biosciences Company Profile

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.

Read More: What Is An Exchange-Traded Fund (ETF)?

Get a free copy of the Zacks research report on Aptose Biosciences (APTO)

For more information about research offerings from Zacks Investment Research, visit

Earnings History and Estimates for Aptose Biosciences (NASDAQ:APTO)

Receive News & Ratings for Aptose Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences and related companies with's FREE daily email newsletter.